# Contractiliteitssensor-geleide CRT-optimalisatie: RESPOND-CRT-trial

*geplaatst 2017-03-07 · Hartfalen · European heart journal · doi 10.1093/eurheartj/ehw526 · https://hartvaat.nl/2017/03/07/contractiliteitssensor-geleide-crt-optimalisatie-respond-crt-trial/*

RESPOND-CRT-trial naar optimalisatie van cardiale resynchronisatietherapie met een contractiliteitssensor. Onderzocht of individuele hemodynamische optimalisatie de CRT-respons verbetert.

## English: Contractility sensor-guided optimization of cardiac resynchronization therapy: results from the RESPOND-CRT trial.

The RESPOND-CRT trial evaluated contractility sensor-guided CRT optimization, testing whether individualized AV and VV delay programming using a sensor-based algorithm improves response rates in heart failure patients.

## Abstract (original, from the publication)

AIMS: Although cardiac resynchronization therapy (CRT) is effective in patients with systolic heart failure (HF) and a wide QRS interval, a substantial proportion of patients remain non-responsive. The SonR contractility sensor embedded in the right atrial lead enables individualized automatic optimization of the atrioventricular (AV) and interventricular (VV) timings. The RESPOND-CRT study investigated the safety and efficacy of the contractility sensor system in HF patients undergoing CRT. METHODS AND RESULTS: RESPOND-CRT was a prospective, randomized, double-blinded, multicentre, non-inferiority trial. Patients were randomized (2:1, respectively) to receive weekly, automatic CRT optimization with SonR vs. an Echo-guided optimization of AV and VV timings. The primary efficacy endpoint was the rate of clinical responders (patients alive, without adjudicated HF-related events, with improvement in New York Heart Association class or quality of life), at 12 months. The study randomized 998 patients. Responder rates were 75.0% in the SonR arm and 70.4% in the Echo arm (mean difference, 4.6%; 95% CI, -1.4% to 10.6%; P < 0.001 for non-inferiority margin -10.0%) (Table 2). At an overall mean follow-up of 548 ± 190 days SonR was associated with a 35% risk reduction in HF hospitalization (hazard ratio, 0.65; 95% CI, 0.46-0.92; log-rank P = 0.01). CONCLUSION: Automatic AV and VV optimization using the contractility sensor was safe and as effective as Echo-guided AV and VV optimization in increasing response to CRT. CLINICALTRIALS.GOV NUMBER: NCT01534234.

Auteurs: Josep Brugada, Peter Paul Delnoy, Johannes Brachmann, Dwight Reynolds, Luigi Padeletti, Georg Noelker, Charan Kantipudi, José Manuel Rubin Lopez, Wolfgang Dichtl, Alberto Borri-Brunetto, Luc Verhees, Philippe Ritter, Jagmeet P Singh

---
Bron: European heart journal, https://doi.org/10.1093/eurheartj/ehw526. Bijgewerkt 2026-07-03T13:25:54Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.